This medication combines two female hormones to relieve menopausal symptoms like hot flashes and vaginal dryness by replacing the estrogen the body no longer produces. It also helps strengthen bones to prevent osteoporosis, and progestin is added to reduce the risk of uterine cancer in women who still have their uterus.[1] Activella is currently being investigated across 17 indications[3], with its most advanced program in Phase 3.[1]
Activella is one of 240 small molecule programs targeting Female. It is currently in Phase 3.
Indications
Total Trials
Active Trials
Competitors
Pipeline
Competition
317 competitors in COVID-19
Activella
Stivarga
Aimovig
Calciferol
Achromycin V
Statins
Rayaldee
Calcium
Pfizer-COVID-19 Vaccine
Olokizumab
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Clinical
Sources